Bertelsmann Investments’ Post

Joining experts from academia, industry, and regulatory bodies to address the complex challenges in drug development, the 2023 AAPS PharmSci 360 event provided an opportunity for Luminex customers to connect with us and share their hands-on experiences utilizing xMAP Technology. Covering the entire spectrum of pharmaceutical sciences, from drug discovery and development to regulatory sciences and more, the conference provided a platform for continuous learning and skill development. Check out our recent blog post, “AAPS PharmSci 360 2023: Making Strides to Tackle Complexity in Drug Development,” where we share what we learned from attending. https://hubs.li/Q02gCMDJ0

Exciting news in the pharmaceutical industry! Gedeon Richter has chosen Trial Interactive's eClinical platform to streamline their TMF operations for upcoming clinical trials. The platform, designed by clinical professionals, offers a secure, AI-enhanced user experience to improve speed and quality across all stages of product development. By integrating Trial Interactive's solution, Gedeon Richter aims to enhance efficiency and maintain inspection readiness in their clinical operations. Learn more about this innovative partnership here: [link to the article]

Check out our latest Almac Voice blog on “Potential impact of IVDR on diagnostic testing in Europe - What are the implications for the pharmaceutical industry?” Written by Joe Clune, CDx Commercialisation Consultant and Stewart McWilliams, VP of Quality and Regulatory Affairs at Almac Diagnostic Services, the blog covers the following key topics: - Challenges in the implementation of IVDR - Background – Companion Diagnostics - The evolving landscape of approved tests vs LDTs - Will Europe still have LDTs with IVDR? - What does Pharma need to do? Download now: https://hubs.li/Q02lbndR0 #IVDR #EUIVDR #ClinicalTrials #CompanionDiagnostics #CDx #LabTests

What a webinar about trends and highlights in pharma and medical device landscape organized by Qualistery and Qualio ! #Regulatory #Highlights #Pharmaceuticals #Medicaldevices

90% of drug candidates entering clinical trials fail to achieve regulatory approval. Explore the significant costs associated with failed drugs from real-world examples and gain insights to avoid common pitfalls in navigating the commercialization journey, in our upcoming webinar with Fierce Pharma on April 9, 10am ET. Join Mike Ward, Dee Chaudary, Samantha Chesney, Carolyn Finch, Angela Weidner and Sofia Ataide - as they delve into the costly reality of failed drug and device launches within the pharmaceutical industry. Register here to attend the webinar or access recording: https://lnkd.in/gzJNH5qP #regulatory #clinicaltrials #drugdiscovery

And just like that, registration has come to a close for the 2024 Collaboration Conference. Starting on February 28th, we'll be joined visionary leaders across the industry, all coming together to fuel one goal: commercial success in the pharmaceutical and medical device industries. Let the countdown begin! #lifesciences #MedDevice #CollaborationConference #Pharma #SynergistixConference

DOWNLOAD THE ARTICLE: https://ow.ly/rtxC50SrNgC The European Parliament has adopted a revision of pharmaceutical legislation, aiming to enhance medicine supply security, improve accessibility and support EU pharmaceutical innovation. Download the article for insights from EVERSANA's experts, Monique Martin, SVP of Value and Evidence, and Mike Ryan, GM of Europe, about how to navigate the changing environment.

It's great to be recognised by Pharma Tech Outlook for our truly revolutionary AI-enabled Veraciti™ system, helping ensure labeling compliance in Pharma and other regulated industries . Watch this space for more from Kallik in 2024! #pharmaindustry #labelingsolutions #compliance #awards #labeling

"Stay ahead with MedLink Pharma Services! 🚀 Dive into the latest trends shaping the pharmaceutical and medical business industries. Read more on our blog. #IndustryInsights #DataTrends""Read the full article at https://lnkd.in/eb-WBNPv"#IndustryTrends #PharmaInsights #DataTrends #BusinessStrategy #IndustryKnowledge #StayInformed #PharmaAnalytics #MedLinkBlog #TrendingTopics #DataInPharma

We at Medialis Ltd are pleased to share the first of a series of updates on the #medicalaffairs principles underlying our work, the four pillars of our medical #thirty22 RWE strategy in the pharmaceutical industry, #rarediseases and orphan drugs. Pillar 1 of our strategy focuses on the application of Neutral theory to construct measurement problems in clinical trials and clinical studies.   Neutral theory allows us to quantify the accuracy of construct measures used as endpoints against an aspirational Neutral list, providing a measure not only of where we are in terms of construct measurement accuracy but also where we are striving to be.  We've Neutral theory to disease-specific Quality-of-Life and disease-severity scales, aiming to increase the accuracy of measurement in clinical studies and thus, patient classification.